Lumos Inventory from 2010 to 2024
| LUMO Stock | USD 2.48 0.03 1.20% |
Inventory | First Reported 2010-12-31 | Previous Quarter -115.2 K | Current Value -121 K | Quarterly Volatility 2 M |
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
Lumos | Inventory |
Latest Lumos Pharma's Inventory Growth Pattern
Below is the plot of the Inventory of Lumos Pharma over the last few years. It is Lumos Pharma's Inventory historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
| Inventory | 10 Years Trend |
|
Inventory |
| Timeline |
Lumos Inventory Regression Statistics
| Arithmetic Mean | 43,923 | |
| Coefficient Of Variation | 4,621 | |
| Mean Deviation | 1,032,175 | |
| Median | (128,000) | |
| Standard Deviation | 2,029,594 | |
| Sample Variance | 4.1T | |
| Range | 9.1M | |
| R-Value | (0.14) | |
| Mean Square Error | 4.3T | |
| R-Squared | 0.02 | |
| Significance | 0.62 | |
| Slope | (63,468) | |
| Total Sum of Squares | 57.7T |
Lumos Inventory History
Other Fundumenentals of Lumos Pharma
About Lumos Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Lumos Pharma income statement, its balance sheet, and the statement of cash flows. Lumos Pharma investors use historical funamental indicators, such as Lumos Pharma's Inventory, to determine how well the company is positioned to perform in the future. Although Lumos Pharma investors may use each financial statement separately, they are all related. The changes in Lumos Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lumos Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lumos Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lumos Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Inventory | -115.2 K | -121 K | |
| Change To Inventory | 105.8 K | 111.1 K | |
| Inventory Turnover | 5.41 | 5.68 | |
| Days Of Inventory On Hand | 54.70 | 57.43 | |
| Days Of Inventory Outstanding | 54.70 | 57.43 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Lumos Stock
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:Check out the analysis of Lumos Pharma Correlation against competitors. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.58) | Revenue Per Share 0.188 | Quarterly Revenue Growth (0.76) | Return On Assets (0.54) | Return On Equity (1.06) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.